Carbamazepine (CBZ) is a widely prescribed anticonvulsant whose use is often associated with idiosyncratic hypersensitivity. Sera of CBZ-hypersensitive patients often contain anti-CYP3A antibodies, including those to a CYP3A23 K-helix peptide that is also modified during peroxidative CYP3A4 heme-fragmentation. We explored the possibility that cytochromes P450 (P450s) such as CYP3A4 bioactivate CBZ to reactive metabolite ( 
been reported, which are proposed to result from the simultaneous binding of multiple substrate molecules and consequent substrate cooperativity within the CYP3A4 active site (Shou et al., 1994; Ueng et al., 1997; Harlow and Halpert, 1998) . Covalent modification of the CYP3A4 active site has been shown to alter the kinetics of CYP3A4 catalysis, indicating the existence of multiple binding sites (Schrag and Wienkers, 2001; Khan et al., 2002) . The recently reported crystal structure of CYP3A4 complexed with two molecules of ketoconazole suggested that the atypical kinetics displayed by CYP3A4 could be the result of multiple coexistent binding modes at the active site (Williams et al., 2004; Yano et al., 2004; Ekroos and Sjogren, 2006) . The finding that CBZ-modified CYP3A4 still retains considerable functional activity led us to investigate the altered enzyme kinetic profile of CBZ-modified CYP3A4.
Materials and Methods
Materials. CBZ, testosterone, 6␤-hydroxytestosterone, GSH, NADPH, EDTA, Hepes, sodium cholate, catalase, magnesium chloride (MgCl 2 ), and ethyl acetate (EtOAc) were purchased from Sigma-Aldrich (St. Louis, MO).
[ 3 H]CBZ was purchased from Amersham Biosciences (Piscataway, NJ). Erythromycin was purchased from Calbiochem (San Diego, CA), and the N-desmethylerythromycin standard was synthesized by Pfizer Inc. (San Diego, CA). L-␣-Dilauroylphosphatidylcholine, L-␣-dioleyl-sn-glycerophosphatidylcholine, and phosphatidyl-serine were purchased from Doosan Serdary Research Laboratories (Englewood Cliffs, NJ). Microsomes (Supersomes; BD Gentest, Woburn, MA) from baculovirus-infected insect cells expressing CYP3A4 along with coexpressed human NADPH-cytochrome P450 reductase (P450 reductase) and human cytochrome b 5 (b 5 ) were purchased from BD Gentest. Ni 2ϩ -NTA resin was purchased from Qiagen (Valencia, CA). The recombinant CYP3A4(His) 6 was expressed in Escherichia coli DH5␣FЈ cells and purified exactly as described previously (Wang et al., 1998; Xue et al., 2001) . Rat liver b 5 and P450 reductase were purified from phenobarbital-pretreated male rat liver microsomes as previously reported (Licad-Coles et al., 1997) .
Determination of CBZ Covalent Binding to Functionally Reconstituted Recombinant CYP3A4. Purified recombinant CYP3A4(His) 6 , assayed spectrophotometrically (Wang et al., 1998) , was functionally reconstituted with P450 reductase and cytochrome b 5 at a previously determined optimal molar ratio of CYP3A4/P450 reductase/b 5 of 1:4:2 using testosterone 6␤-hydroxylase as the functional probe as described (Wang et al., 1998) . The reagents were added at 4°C in the following order in a final volume of 1 ml: lipid mixture (L-␣-dilauroylphosphatidylcholine/L-␣-dioleyl-sn-glycerophosphatidylcholine/phosphatidylserine, 1:1:1, w/w, 20 g), sodium cholate (200 g), cytochrome b 5 (500 pmol), P450 reductase (1000 pmol), CYP3A4 (250 pmol), and GSH (1.5 mol). The mixture was reconstituted at room temperature for 10 min and then placed back on ice. The following reagents were then added in order to a final volume of 1 ml: Hepes (50 mM, pH 7.85), 20% glycerol, catalase (200 U), EDTA (1 mM), water, MgCl 2 (30 mM), and CBZ with [ 3 H]CBZ (1 mM and 1.25 Ci/ml final, dissolved in methanol). After a 3-min preincubation at 37°C, NADPH (1 mM final) was added to initiate the reaction. Controls for nonspecific binding were prepared as described except that the incubations contained no NADPH. Carrier rat liver microsomal protein (10 mg) was added after a 30-min incubation, and the incubation was immediately quenched with EtOAc. The protein precipitate was then washed three times with methanol containing 5% H 2 SO 4 , followed by three washes with a mixture of ethanol and ethyl ether (3:1, v/v) and two washes with 80% aqueous methanol. The pellet was dissolved in 1 N NaOH. An aliquot was neutralized with 1 N HCl, and liquid scintillation fluid was added for radioactivity determination. The protein concentration of another aliquot was also determined to calculate the protein recovery. The stoichiometry of covalent binding was determined on the basis of the recovered residual radioactivity irreversibly bound to the precipitated protein pellet. Higher concentrations of GSH up to 4 mM were also included in the incubation mixture to study the effect of GSH on the covalent binding.
Determination of CBZ-Covalent Binding to CYP3A4 Supersomes. A mixture of CYP3A4 Supersomes (100 pmol), isocitric acid (5 mM), isocitric acid dehydrogenase (0.5 U/ml), potassium phosphate buffer (100 mM, pH 7.4), CBZ with [ 3 H]CBZ (1 mM and 1.25 Ci/ml final, dissolved in methanol), and EDTA (1 mM) was preincubated for 3 min at 37°C. NADPH (1 mM, final) was added to start the reaction (final volume, 0.5 ml). Controls for nonspecific binding consisted of exactly similar incubations without NADPH. Carrier microsomal protein (10 mg) was added after a 30-min incubation, and the reaction was terminated with EtOAc. The protein pellet was washed as detailed above. The stoichiometry of covalent binding was calculated on the basis of the recovered residual radioactivity irreversibly bound to the protein pellet as described above. When the effect of GSH on the CBZ covalent binding to CYP3A4 was assessed, GSH up to 4 mM was also included in the incubation mixture.
Reisolation 6 adduct was subjected to SDS-PAGE analyses and the protein quantified by densitometry relative to the content of the purified CYP3A4 used as the starting material and electrophoresed in parallel. The stoichiometry of covalent binding was calculated on the basis of the residual radioactivity irreversibly bound to the recombinant CYP3A4 protein.
Testosterone 6␤-Hydroxylase Activity of the CBZ-Modified CYP3A4. After a 30-min incubation of CBZ with either CYP3A4 Supersomes or the functionally reconstituted purified recombinant CYP3A4 as described above, an aliquot of CYP3A4 (10 pmol) was added to a secondary reaction mixture (1 ml final volume) containing testosterone (1.9 -500 M) and other reagents as described above. The reaction was initiated by the addition of NADPH (1 mM), allowed to run at 37°C for 20 min, and then quenched with EtOAc. Progesterone was included as an internal control. The metabolites were extracted twice with EtOAc, dried down under N 2 , and assayed by high-performance liquid chromatography with peak area quantification for 6␤-hydroxytestosterone, the major product, as described previously (Xue et al., 2001) .
Kinetic analysis of CYP3A4 6␤-hydroxylation of testosterone was performed using the Hill equation:
where is the enzyme velocity, C is the substrate concentration, K m is the substrate concentration at the half-maximum velocity, n is the Hill coefficient, and V max is the maximal velocity. The nonlinear, least-squares curve fitting was carried out with IGOR Pro 4.01 (WaveMetrics Inc., Lake Oswego, OR).
Time-Dependent Inhibition of CYP3A4 Testosterone Hydroxylase Activity. Functionally reconstituted, purified recombinant CYP3A4 was incubated with various concentrations of CBZ (0 -1000 M) at 37°C as described above. Aliquots of the mixtures (40 l containing 10 pmol CYP3A4) were taken at various time intervals (0 -20 min) and added to a secondary reaction mixture (1 ml final volume) containing 250 M testosterone, Hepes (50 mM, pH 7.85), 20% glycerol, catalase (200 U), EDTA (1 mM), GSH (1.5 mM), and MgCl 2 (30 mM) for the determination of the residual testosterone 6␤-hydroxylase activity as described above. CYP3A4 Supersomes were incubated with 150 M and 1000 M of CBZ at 37°C as described above. Aliquots of the mixtures (100 l containing 10 pmol CYP3A4) were taken at various time intervals (0 -30 min) and added to a secondary 1-ml reaction mixture containing 250 M testosterone, isocitric acid (5 mM), isocitric acid dehydrogenase (0.5 U/ml), potassium phosphate buffer (100 mM, pH 7.4), EDTA (1 mM), and GSH (1.5 mM) for the determination of the residual testosterone 6␤-hydroxylase activity as described above.
Erythromycin N-Demethylase Activity of the CBZ-Modified CYP3A4. After a 30-min incubation of CBZ with CYP3A4 Supersomes as described above, an aliquot of CYP3A4 (1 pmol) was added to a secondary reaction mixture (0.2 ml, final volume) containing erythromycin (1-350 M) and other reagents as described above. The reaction was initiated by the addition of NADPH (1 mM), allowed to run at 37°C for 15 min, and then quenched with 0.2 ml acetonitrile. A 10-l aliquot was subjected to liquid chromatographymass spectrometric analysis for metabolite quantification. N-Desmethyleryth-romycin was quantified by Shimadzu LC-10AD VP binary pumps (Shimadzu, Columbia, MD) coupled with a Q-Trap 4000 (Applied Biosystems/MDS Sciex, Foster City, CA). The metabolite was separated by a Synergi Fusion-RP column (4 m, 100 ϫ 2.0 mm; Phenomenex, Torrance, CA) at a flow rate of 0.2 ml/min. A gradient of (A) water with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid was applied as follows: initiated with 20% B for 1 min and then increased in a linear manner to 65% at 2.3 min and to 100% at 4.5 min. The gradient was maintained at 100% B for 5 min and then decreased to 20% at 5.5 min. The column was allowed to equilibrate at 20% solvent B for 0.5 min before the next injection. The high-performance liquid chromatography effluent going to the mass spectrometer was directed to waste through a divert valve for the initial 1 min after sample injection. The Q-Trap 4000 Electrospray-MS was operated in the positive ionization mode by applying to the capillary a voltage (ion spray) of 4.5 kV. Nitrogen was used as curtain gas, as well as nebulizing (GS1) and turbo spray gas (GS2, heated at 450°C), with the optimum values set, respectively, at 36, 50, and 40 (arbitrary values). Collision-activated dissociation was performed at 6 (arbitrary value) with nitrogen as collision gas. Declustering potential was set at 41 V, whereas entrance potential was set at 10 V; collision energy was optimized at 51 eV. The multiple reaction monitoring transitions used were 7203144 for N-desmethylerythromycin. The concentrations were determined by means of a standard curve, wherein N-desmethylerythromycin was dissolved in the same incubation and quench buffer to prepare standards with concentrations ranging from 0.1 to 100 g/ml. Kinetic data analyses of CYP3A4-dependent erythromycin N-demethylase were performed as described above for testosterone 6␤-hydroxylase.
Flexible Docking of CBZ, Testosterone, and Erythromycin in CYP3A4 Crystal Structure. Initial flexible docking of testosterone into the active site of CYP3A4 [Protein Data Bank accession code 1w0g (Williams et al., 2004) ] was carried out with FlexX, version 1.7.6, implemented in the SYBYL, version 7.0 (Tripos Inc., St. Louis, MO.). The docking solutions were ranked according to CScore. Visual inspection identified a low energy binding mode compatible with 6␤-hydroxylation of testosterone, and this protein-ligand complex was used as a starting point for further flexible docking experiments with testosterone or CBZ using the Pfizer in-house docking and scoring software (Gehlhaar et al., 1995 (Gehlhaar et al., , 1999 Marrone et al., 1999) . Restrained docking of CBZ into the active site of the previously identified complex anchoring its 2, 3, 10, or 11 carbon near the sulfur of Cys239 was performed and followed by proteinligand minimization to yield a low energy binding mode. In separate experiments, a second testosterone was docked into the previously identified 3A4-testosterone complex using a method that allowed the protein to move throughout the docking simulation via discrete minimization. Erythromycin was also docked into the 1w0g structure using a restrained docking method that anchored the site of metabolism near the heme iron and was followed by a docking simulation that allowed protein flexibility.
Results
Time-Dependent Inactivation of CYP3A4 Testosterone 6␤-Hydroxylase Activity by CBZ. The testosterone 6␤-hydroxylase activity of both CYP3A4 Supersomes and functionally reconstituted purified recombinant CYP3A4(His) 6 was reduced with increasing preincubation time with CBZ ( Fig. 1, A and B) . However, the timedependent functional inactivation of CYP3A4 was not exacerbated by increasing concentrations of CBZ. Instead, the greatest inactivation of dmd.aspetjournals.org enzyme activity, particularly with the functionally reconstituted purified recombinant CYP3A4, was observed in the absence of CBZ (Fig.  1B) , and inclusion of CBZ increasingly protected the enzyme from time-dependent inactivation. Functionally reconstituted recombinant CYP3A4(His) 6 incubated with NADPH alone also showed a significant reduction in its characteristic reduced CO-binding 450 nmabsorption spectrum (data not shown). These findings do not support the mechanism-based inactivation of CYP3A4 by CBZ; however, they are consistent with significant oxidative uncoupling associated with these CYP3A4 systems containing a 1:4 M excess of P450 reductase in the absence of substrates.
Determination of CBZ-Covalent Binding to CYP3A4 Protein.
Incubation of CYP3A4 Supersomes with [
3 H]CBZ resulted in covalently bound CBZ to CYP3A4. After extensive organic solvent washes to remove free nonspecifically bound [ 3 H]CBZ, the residual radioactivity associated with the protein pellet was monitored. The stoichiometry (molar ratio) of CBZ/CYP3A4 protein was calculated to be 1.58:1. Inclusion of GSH (1.5 mM) in the incubation reduced this molar ratio to 1.09. Similar covalent binding analyses with the recombinant CYP3A4, functionally reconstituted in the presence of GSH (1.5 mM) and using the same protein precipitation method, yielded a stoichiometry of CBZ-CYP3A4 adduct of 0.79:1.
Determination of the Covalent Binding by Reisolation of the CBZ-CYP3A4(His) 6 Adduct. The stoichiometry of the adduct was also determined by isolating the CBZ-modified CYP3A4(His) 6 protein after incubation of the functionally reconstituted recombinant CYP3A4(His) 6 with [ 3 H]CBZ by Ni 2ϩ -NTA affinity chromatography. Unbound CBZ and other constituents of the incubation mixture such as P450 reductase and b 5 were removed by extensive washing, as monitored by SDS-PAGE analyses, which showed that the residual radioactivity was associated solely with the eluted CYP3A4(His) 6 and that the CBZ-CYP3A4(His) 6 adduct was clearly separated from P450 reductase and b 5 . The stoichiometry of the isolated CBZ-CYP3A4(His) 6 adduct was calculated to be 1 Ϯ 0.4 pmol CBZ/pmol CYP3A4 on the basis of its residual radioactivity. Together, these findings indicated that the bioactivated CBZ covalently modified CYP3A4, possibly within the active site of this enzyme, to form a CBZ-CYP3A4 protein adduct.
Enzyme Kinetics of CBZ-Modified CYP3A4. Influence on testosterone 6␤-hydroxylation. To explore the possible site of CBZ adduction, its effect on the cooperativity with a known CYP3A4 substrate testosterone was probed. Incubation of CYP3A4 Supersomes with testosterone yielded the previously reported sigmoidal kinetics as evidenced by the curved Eadie-Hofstee plot ( Fig. 2A ; n ϭ 1.2). The kinetic values obtained after the data were fitted to the Hill equation are shown in Table 1 . CYP3A4-dependent testosterone 6␤-hydroxylase activity was inhibited when CYP3A4 was preincubated with CBZ in the presence or absence of NADPH. When preincubated with CBZ in the absence of NADPH, CYP3A4 still retained its sigmoidal kinetics ( Fig. 2B; n ϭ 1.3) . In contrast, after preincubation with NADPH, which, as described above, results in a covalent 1:1 molar CBZ-adduction of CYP3A4, the CBZ-modified enzyme displayed an almost hyperbolic kinetic profile of testosterone 6␤-hydroxylation ( Fig. 2C ; n ϭ 1.0). The K m for testosterone was unaffected when CYP3A4 was preincubated with CBZ without NADPH. A larger increase in K m was observed when CYP3A4 was covalently modified by CBZ in the presence of NADPH. However, the V max values, albeit lower, were not substantially different after preincubation with CBZ in the presence or absence of NADPH (Table 1) .
A similar sigmoidal kinetic profile, characterized by a curved Eadie-Hofstee plot ( Fig. 3A ; n ϭ 1.4), was also observed for the testosterone 6␤-hydroxylase activity of functionally reconstituted recombinant CYP3A4. The rate of 6␤-hydroxytestosterone formation was inhibited in the presence of CBZ, even in the absence of NADPH. Eadie-Hofstee analyses of the enzyme activity in the presence of CBZ but without preincubation with NADPH revealed a similar sigmoidal profile, although the presence of CBZ lowered the Hill coefficient ( Fig. 3B; n ϭ 1.2) . The K m of testosterone increased in the presence of CBZ, thereby suggesting CBZ competition at the testosteronebinding site. After covalent modification of CYP3A4 by preincubation with CBZ in the presence of NADPH, its residual testosterone 6␤-hydroxylase activity yielded an almost hyperbolic profile with a linear Eadie-Hofstee plot (Fig. 3C) . The Hill coefficient n also decreased to 1.1 (Table 1) . CBZ-modified CYP3A4 also displayed a lower binding affinity toward testosterone as evidenced by the increased K m value, whereas the V max value only slightly decreased when NADPH was included in the preincubation (Table 1) .
Influence on erythromycin N-demethylation. To further assess the effect of covalent CBZ-induced modification on CYP3A4-dependent function, the N-demethylation of erythromycin, another prototypic CYP3A4 substrate with an affinity comparable to that of testosterone and thus a competitive substrate inhibitor of CYP3A4-dependent testosterone 6␤-hydroxylase activity (Wang et al., 1997) , was examined. However, the kinetic data obtained for erythromycin N-demethylation after CBZ-induced modification of CYP3A4 Supersomes were scattered and failed to provide a good fit to either the Hill or Michaelis-Menten equation. Nevertheless, curve fitting yielded comparable V max values for CYP3A4-dependent erythromycin N-demethylation with (3.61 Ϯ 0.22 nmol/nmol CYP3A4/min) or without (3.60 Ϯ 0.58 nmol/nmol CYP3A4/min) CBZ-induced covalent modification of the enzyme (Fig. 4, A , B, and C; Table 2 ). These results suggested that, contrary to the results obtained with testosterone as a substrate, CBZ-induced covalent modification of CYP3A4 had no significant effect on erythromycin N-demethylation.
Flexible Docking of CBZ, Testosterone, and Erythromycin in CYP3A4 Crystal Structure. Initial dockings with testosterone into the active site of apo CYP3A4 identified a low energy binding pose of testosterone near the heme that is consistent with its 6␤-hydroxylation. This complex was used as the starting point for further docking experiments. When a second molecule of testosterone is docked into the active site using an induced fit method, which allows minimal protein flexibility during docking, one of the low energy binding modes places the second testosterone partly in the active site but extending toward the surface of the protein in a channel that is defined by the helix GЈ to helix G loop, the B-C loop, and the I helix. This docking did not require any repositioning of the first testosterone bound (Fig. 5A) .
Restrained docking of CBZ yielded poses that would be compatible with adduct formation with Cys239 by carbon 2 or 3 of CBZ (Fig. 5A) . Furthermore, low energy binding modes were also observed when the 10 or 11 carbon of CBZ was restrained toward Cys239, suggesting that adduct formation arising from the 10,11-epoxide intermediate is also possible (data not shown). All of the restrained docking binding poses observed for CBZ, regardless of which carbon was anchored, are compatible with testosterone binding near the heme but would cause steric clashes with a second molecule of testosterone bound in the active site as described previously (Fig. 5A) . On the other hand, restrained docking of erythromycin in the apo active site of 1w0g yielded a low energy binding pose that allowed approach of its dimethylamino nitrogen consistent with the known N-demethylation of erythromycin by CYP3A4 (Fig. 5B) .
Discussion
In vitro studies with recombinant human P450s expressed in yeast have documented the covalent binding of CBZ to proteins belonging to the P450 subfamilies 1A, 2C, and 3A (Wolkenstein et al., 1998) . However, no mechanism-based inactivation of the covalently modified P450s was detected. Similarly, no evidence for the functional inactivation of human CYP2C8, CYP2C9, or CYP3A4 could be found after preincubation of human liver microsomes with CBZ in the presence of NADPH (Masubuchi et al., 2001) . In the present study, we show that CYP3A4 Supersomes formed an adduct with [ 3 H]CBZ with a molar stoichiometry of 1.58:1 (CBZ/CYP3A4). This molar NADPHϪ, CBZϪ: preincubation of CYP3A4 in the absence of NADPH and CBZ followed by assay of testosterone 6␤-hydroxylase activity; NADPHϪ, CBZϩ: preincubation of CYP3A4 with CBZ but without NADPH followed by assay of testosterone 6␤-hydroxylase activity; NADPHϩ, CBZϩ: preincubation of CYP3A4 in the presence of both NADPH and CBZ followed by assay of testosterone 6␤-hydroxylase activity. ratio was reduced to approximately 1:1 by inclusion of GSH (1.5 mM) in the incubation; however, this molar ratio was not further affected by higher concentrations of GSH (up to 4 mM). Because both CYP3A4 Supersomes and yeast microsomes contain various other proteins, the possibility existed that proteins other than CYP3A4 were covalently modified by CBZ and thus either were acid coprecipitated with CYP3A4 or comigrated with it after SDS-PAGE. We therefore examined a simpler system consisting of purified functionally reconstituted CYP3A4, wherein after incubation with CBZ, the CBZ-modified recombinant CYP3A4(His) 6 was readily separated from P450 reductase and b 5 by Ni 2ϩ -NTA affinity chromatography. A similar 1:1 molar ratio was observed in this CBZ-modified CYP3A4(His) 6 system, thus suggesting that CYP3A4 expressed in baculovirus (CYP3A4 Supersomes) and yeast (Wolkenstein et al., 1998) was most likely the only protein that was covalently modified by CBZ. The fact that GSH (1.5 mM), normally included in CYP3A4 functional reconstitution systems, failed to reduce this 1:1 molar ratio of CBZ/ CYP3A4 suggested that CBZ was covalently bound within the CYP3A4 active site, thereby making it somewhat inaccessible for nucleophilic trapping by GSH.
We find it noteworthy, however, that a considerably greater extent of CBZ-induced covalent binding occurs in the absence of GSH. This suggests that individuals with low hepatic GSH content, which may result from pharmacological depletion by coadministered drugs, dietary deprivation, inadequate repletion of GSH-precursors, or even defective GSH synthesis, may be at a higher risk for enhanced covalent modification of P450s. Subsequent proteolytic processing of such CBZ-modified P450s for antigenic presentation may contribute to the pathogenesis of the hypersensitivity/idiosyncratic reactions. Although the mechanism of CBZ bioactivation and covalent binding has yet to be precisely elucidated, previous studies have suggested that CBZ-derived arene oxide, quinone, iminoquinone, catechol, quinone 
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at ASPET Journals on June 22, 2017 dmd.aspetjournals.org methide, and/or epoxide could be viable reactive metabolites that chemically modify P450s (Madden et al., 1996; Pearce et al., 2002 Pearce et al., , 2005 Bu et al., 2005 ) (Scheme 1). Furthermore, although the precise site of this binding remains to be identified, conceivably Cys239 could be a plausible target as in raloxifene-mediated CYP3A4 adduction (Baer et al., 2007) . Nevertheless, our finding that CBZ covalently modifies CYP3A4 (possibly at the active site) is intriguing in view of the fact that it maims but does not inactivate the enzyme, consistent with the report that CBZ is not a mechanism-based CYP3A4 inactivator (Masubuchi et al., 2001) .
The unusual sigmoidal kinetic interactions exhibited by CYP3A4 have been rationalized by the binding of multiple substrate molecules at more than one site within the CYP3A4 active site (Shou et al. ,   TABLE 2 Kinetic parameters of erythromycin N-demethylation by CYP3A4 Supersomes before and after CBZ-modification NADPHϪ, CBZϪ: preincubation of CYP3A4 in the absence of NADPH and CBZ followed by assay of erythromycin N-demethylase; NADPHϪ, CBZϩ: preincubation of CYP3A4 with CBZ but without NADPH followed by assay of erythromycin N-demethylase; NADPHϩ, CBZϩ: preincubation of CYP3A4 in the presence of both NADPH and CBZ followed by assay of erythromycin N-demethylase. Ueng et al., 1997; Harlow and Halpert, 1998; Korzekwa et al., 1998) . Similar sigmoidal kinetics of CYP3A4-catalyzed CBZ metabolism imply multiple CBZ-binding sites within the CYP3A4 active site (Nakamura et al., 2003) . However, the observed 1:1 molar stoichiometry of the CBZ-CYP3A4 adduct suggests that only one substrate binding site of CYP3A4 was covalently modified by CBZ, with the other CBZ-binding sites remaining unscathed. Furthermore, not only was the CYP3A4-characteristic testosterone 6␤-hydroxylase activity only slightly reduced when CYP3A4 was covalently modified by CBZ, but such modification also failed to affect CYP3A4-dependent erythromycin N-demethylase activity. CBZ also fails to functionally inactivate CYP3A4 in a mechanism-based manner in human liver microsomes (Masubuchi et al., 2001) . Indeed, the presence of endogenous steroids, such as testosterone in the incubation, drastically increases CYP3A4-dependent CBZ 10,11-epoxidase activity and alters its kinetic profile from sigmoidal to hyperbolic (Michaelis-Menten type) (Nakamura et al., 2003) . Such substrate cooperativity at the CYP3A4 active site was taken as evidence for a two-site substratebinding model. Consistent with this model, our study showed that a complete block of one CYP3A4 substrate-binding site by CBZ covalent modification altered the kinetic profile of CYP3A4-dependent testosterone 6␤-hydroxylation from sigmoidal to near-hyperbolic (Michaelis-Menten type). Due to the higher CYP3A4 binding affinity of testosterone (K m , 30 -100 M) than that of CBZ (K m , 250 M) (Pelkonen et al., 2001 ), CBZ does not compete effectively for all the CYP3A4-testosterone substrate binding sites, thus leading to the retention of its CYP3A4 sigmoidal kinetic profile. Interestingly, CBZ inclusion led to a greater reduction of the Hill coefficient for the functionally reconstituted purified CYP3A4(His) 6 (n ϭ 1.4 to n ϭ 1.2) but an increase for CYP3A4 Supersomes (from n ϭ 1.2 to n ϭ 1.3), which may be explained by the higher binding affinity of testosterone to CYP3A4 Supersomes (K m ϭ 41.0 M) than to the functionally reconstituted purified CYP3A4(His) 6 (K m ϭ 81.5 M).
CYP3A4 Supersomes
In silico docking studies were undertaken in an attempt to rationalize the effect of CBZ-modification of CYP3A4 on its atypical testosterone 6␤-hydroxylation kinetics. Although the presence of multiple binding sites and consequent substrate cooperativity within the CYP3A4 active site is supported by the simultaneous docking of both ␣-naphthoflavone and testosterone into the apo crystal structure, the recently reported CYP3A4 crystal structure with two complexed ketoconazole molecules confirms that the CYP3A4 active site can simultaneously accommodate even relatively large substrate ligands (Yano et al., 2004; Ekroos et al., 2006) . In a similar manner, our in silico experiments suggest that at least two molecules of testosterone can simultaneously bind in the CYP3A4 active site. One testosterone is bound near the heme in an orientation compatible with its 6␤-hydroxylation and a second extends toward the surface of the protein via an access channel, which also contains Cys239 located on the loop between helix GЈ and helix G (Fig. 5) . In the absence of any large conformational alterations upon adduct formation, CBZ bound at Cys239 would sterically hinder testosterone binding at this second site but would not affect its catalytic binding near the heme. The persistence of a relatively robust testosterone 6␤-hydroxylase activity after CBZ-modification of the CYP3A4 active site is thus consistent not only with the successful simultaneous docking of both CBZ and testosterone therein but also the plausible existence of multiple binding sites within the capacious CYP3A4 active site. Indeed, this particular CYP3A4 feature is further underscored by our findings that the N-demethylation of erythromycin is largely unaffected by CBZ-induced CYP3A4 covalent modification. Our docking analyses reveal that this relatively large macrolide apparently assumes a slightly different orientation within the CYP3A4 active site, which would be unaffected by the CBZ modification in the access channel, thereby precluding any steric/kinetic effects such as those observed with testosterone 6␤-hydroxylation (Fig. 5B) .
Intriguingly, however, such CBZ-mediated alteration of testosterone hydroxylation kinetic profile from sigmoidal to near hyperbolic following its CYP3A4 active site modification may rationalize the reported failure of midazolam (MDZ) hydroxylation to exhibit any detectable homotropic cooperativity (Khan et al., 2002) , in spite of its putative binding at multiple sites within the CYP3A4 active site. The covalent modification of one of these sites during its mechanismbased inactivation via 1Ј-OH MDZ formation may similarly conceal its sigmoidal kinetic profile. Moreover, such MDZ-mediated covalent modification is reported to differentially inhibit CYP3A4-catalyzed oxidations of testosterone and triazolam, thereby providing further evidence for the possible existence of multiple spatially distinct binding sites or binding orientations for each of these substrates (Schrag and Wienkers, 2001; Khan et al., 2002) . Additional evidence for plausible MDZ binding at two distinct albeit overlapping CYP3A4 active sites may be derived from the findings of its regioselective hydroxylation to either 1Ј-OH MDZ or 4-OH MDZ by CYP3A4 and several of its active site-directed mutants (Khan et al., 2002) .
Lastly, it is to be noted that significant time-dependent enzyme Leeder, unpublished observations). B, same as in (A) except that erythromycin, docked in a pose compatible with its N-demethylation, is also shown in a red stick representation. Please note that although these particular dockings are consistent with our in vitro kinetic data, they represent an in silico attempt at capturing a very dynamic system. Other potential low energy binding modes for the second TS molecule in the CYP3A4 active site outside of the access channel are also possible.
CARBAMAZEPINE METABOLISM BY CYP3A4
at ASPET Journals on June 22, 2017 dmd.aspetjournals.org inactivation of both CYP3A4 Supersomes and functionally reconstituted purified recombinant CYP3A4(His) 6 was observed upon incubation with NADPH alone, consistent with marked oxidative uncoupling associated with these CYP3A4 systems in the absence of substrates (Zangar et al., 2004; Denisov et al., 2006) . Interestingly, CBZ inclusion in these incubations protected CYP3A4 from this time-dependent inactivation, and this protection was magnified by increasing CBZ concentrations, thereby precluding the detection of any CBZ-induced mechanism-based inactivation of CYP3A4 testosterone 6␤-hydroxylase activity. In summary, CYP3A4-mediated bioactivation of CBZ generated a covalent CBZ-CYP3A4 adduct with a molar ratio of 1:1 (CBZ/ CYP3A4). The formation of this drug-protein adduct could not be abolished by GSH inclusion. However, the CBZ-modified CYP3A4 was still functionally active, albeit at a reduced functional level with testosterone as the substrate. This CYP3A4 covalent modification by CBZ altered its testosterone 6␤-hydroxylase kinetic profile from sigmoidal to near-hyperbolic Michaelis-Menten type, thereby suggesting that CBZ-mediated modification occurs within the CYP3A4 active site. Covalent modification of CYP3A4 SCHEME 1. Proposed reactive metabolites and the covalent modification of CYP3A4 active site. The iminoquinone is reportedly derived from 2-hydroxycarbamazepine (Pearce et al., 2005) . Other reactive metabolites include 2,3 arene oxide, 2,3 catechol, dihydroquinone, and the 3-quinone methide.
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